Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12 Suppl
|
| pubmed:dateCreated |
1998-1-2
|
| pubmed:abstractText |
Patients with B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) frequently have splenomegaly, which has been reported to cause poor tumor targeting of radiolabeled antibodies. Consequently, patients with splenomegaly have been ineligible for some trials of radioimmunotherapy because of the assumption that they would not benefit.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0008-543X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
80
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2553-7
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9406709-Humans,
pubmed-meshheading:9406709-Iodine Radioisotopes,
pubmed-meshheading:9406709-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:9406709-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9406709-Radioimmunotherapy,
pubmed-meshheading:9406709-Radiotherapy Dosage,
pubmed-meshheading:9406709-Splenomegaly
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies.
|
| pubmed:affiliation |
University of California at Davis, School of Medicine, Sacramento, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.
|